UK-based early-stage technology investor Mercia Fund Management has provided £300,000 ($450,000) to Coventry University spinout InoCardia.
The company is commercialising drug safety technology which looks at the effect of substances on heart tissue. Along with £700,000 provided by state-backed body Innovation UK, the firm will now focus on building its team and accelerating commercialisation.
Helen Maddock, founder of InoCardia, said: “It is with great pleasure that we accept further investment from Mercia. Their support has been invaluable as we seek to commercialise our research and build partnerships with pharmaceutical organisations.”
